Navigation Links
GENova Biotherapeutics secures new cancer drugs targets
Date:9/17/2009

NEW YORK, Sept. 17 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed a collaboration deal with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments.

The two companies are joining forces in their mutual mission to identify, acquire, and out-license promising cancer drugs in an effort that will not only save millions on GENova's R D budget, but at the same time will significant increase GENova's distribution, the deal with Beckpharma is the latest deal in a string of deals that GENova has recently done in a continued effort to increase its IP portfolio and increase its distribution network.

"By combining our efforts with Beckpharma's, we are casting a wider net when it comes to sourcing new cancer drug targets. Beckpharma has close relationships with academic research institutions around the world, and now, through this collaboration, their industry contacts become ours, and vice versa," says Aaron Whiteman, CEO for GENova.

This collaboration will bolster GENova's acquisition activities and funnel more promising drug targets into its drug development pipeline. GENova will also leverage the scientific expertise of Beckpharma's Research and Development Team, as well as its established distribution channels with Big Pharmaceutical companies.

Furthermore, scientists in both GENova and Beckpharma are examining their current IP portfolios to gain insight into possible synergies between their drug targets, and the possibility of making a stronger, better, combined product by coordinating their biotechnologies.

"This is a positive step for GENova," says Whiteman. "Through our collaboration with Beckpharma we are gaining access to their technologies and relationships, and we hope to leverage that to b
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
2. GENova and TheraGlass in advanced negotiations
3. GENova Biotherapeutics forming academic partnerships
4. GENova Biotherapeutics signs collaboration agreement with Prime BioResearch
5. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
6. GENova gains access to Big Pharma
7. GENova appoints Dr. Wang Chong to Scientific Advisory Board
8. GENova appoints Dr. Philip Gould to Scientific Advisory Board
9. GENova issues clarifying press release
10. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
11. GENova files patent for new breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... Oregon State University researcher has found a relationship between ... of autism spectrum disorder in very young children. ... to show a direct relationship between motor skills and ... motor skills should be included in treatment plans for ... professor in OSU,s College of Public Health and Human ...
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... Pregnant immigrants from Sub-Saharan Africa, Latin America ... pregnancy, according to new research from St. Michael,s ... British Journal of Obstetrics and Gynaecology , ... among immigrants and native-born women in six high-immigration ... Spain (Catalonia and Valencia) and the United States ...
(Date:4/23/2014)... at the National Institute of Arthritis and Musculoskeletal and ... of the Ross Prize in Molecular Medicine, conferred by ... . The award will be given on June 9 ... followed by scientific presentations by Dr. O,Shea and other ... of Health. , The award, which includes a $50,000 ...
(Date:4/23/2014)... that rats exposed to high-energy particles, simulating conditions astronauts ... lapses in attention and slower reaction times, even when ... , The cognitive impairments which affected a large ... appear to be linked to protein changes in the ... hold true in humans, suggest it may be possible ...
Breaking Medicine News(10 mins):Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... international body of knowledge to Texas,research center in ... The University of,North Texas Health Science Center ... recently added several new members to its faculty,to ... and,osteopathic manipulative medicine., Anuja Ghorpade has joined ...
... WALTHAM, Mass., Nov. 21 Inverness Medical,Innovations, Inc. (Amex: ... announced public offering on Tuesday. The Company sold a ... offering price of $61.49,per share. The total number of ... the underwriters upon their exercise of their,over-allotment option in ...
... 30,000 Clinic Locations, WASHINGTON, Nov. 21 ... announced the week after Thanksgiving,November 27 to December ... recommendations, influenza vaccination (flu shot) rates in young,children ... age 6 to 23,months were fully immunized for ...
... ATLANTA, Nov. 21 Eclipsys Corporation(R),(Nasdaq: ECLP ... be,participating in the Merrill Lynch Health Services Investor ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys ... 28th at 10:00 a.m. Eastern time. Interested parties ...
... Czymmek, as he points to the video on his computer ... fireworks flash across the screen with every pulsation of the ... there is a large release of calcium with every heartbeat. ... a major problem--perhaps even heart failure. , Czymmek has a ...
... Nov. 21 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... Development (R&D),Day on Wednesday, November 28, 2007 at ... New York., "Amylin is focused on bringing ... our sustainable approach to the,discovery and development of ...
Cached Medicine News:Health News:UNT Health Science Center Appoints Eight New Faculty Members 2Health News:UNT Health Science Center Appoints Eight New Faculty Members 3Health News:Inverness Medical Innovations Announces Closing of Public Offering 2Health News:Asthma Foundation Offers National Flu Shot Finder 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3Health News:New microscope peers into secret lives of cells 2Health News:New microscope peers into secret lives of cells 3Health News:Amylin Pharmaceuticals to Present at Research & Development Day 2
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 26, 2007 /PRNewswire-FirstCall/ --,Replidyne, Inc. today announced ... a novel topical antibiotic that has shown ... including,methicillin-resistant S. aureus (MRSA). The results of ... REP8839 appears safe,well-tolerated and associated with low ...
... in a randomized phase II/III clinical trial,anticipated ... /PRNewswire-FirstCall/ -- Cell,Therapeutics, Inc. (CTI) announced the ... with pixantrone (BBR,2778) resulted in minimal or ... significant cardiac damage.,The studies compared the cardiac ...
Cached Medicine Technology:Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: